Feindt P, Seyfert U T, Volkmer I, Straub U, Gams E
Department of Thoracic and Cardiovascular Surgery, Saarland University Hospital, Homburg/Saar, Germany.
Thorac Cardiovasc Surg. 1994 Aug;42(4):218-21. doi: 10.1055/s-2007-1016491.
Since the introduction of the proteinase inhibitor aprotinin in cardiac surgery, a strong increase of the activated clotting time (ACT) during the extracorporeal circulation phase (ECC) was reported in many clinical studies, but with a lack of correlation between ACT and heparin concentration. In searching for a cause of this inconsistency we investigated different surface activators of the ACT in a clinical study. During ECC ACT was measured in parallel, using a Hemochron device and corresponding tubes (nominally 12 mg celite activator) for celite ACT, and a HemoTec device with corresponding double tubes (nominally 0.1 ml kaolin activator) for kaolin ACT. Under the conditions of ECC, the kaolin ACT values (482 +/- 145 sec) were significantly lower than the celite ACT values (985 +/- 267 sec). These results were confirmed in ex-vivo experiments using an activated partial thromboplastin time (aPTT) model. With heparin alone, aPTT activated with celite and kaolin were similar. Including aprotinin in this model, the celite aPTT showed no correlation to the heparin concentration, whereas the kaolin aPTT remained well correlated to the heparin concentration and similar to the values without aprotinin. With aprotinin alone there were no changes of the aPTT times, whereas the celite ACT times were without any correlation. Our results indicate that using kaolin instead of celite the ACT measurements under aprotinin therapy stay in the same ranges as without application of aprotinin: aprotinin has no detectable influence on kaolin-activated ACT. In our opinion, kaolin should be used as the surface activator for ACT measurements under the conditions of ECC, heparinization, and aprotinin therapy.(ABSTRACT TRUNCATED AT 250 WORDS)
自从在心脏手术中引入蛋白酶抑制剂抑肽酶以来,许多临床研究报告称,在体外循环阶段(ECC)激活凝血时间(ACT)显著延长,但ACT与肝素浓度之间缺乏相关性。为了寻找这种不一致的原因,我们在一项临床研究中调查了ACT的不同表面激活剂。在ECC期间,使用Hemochron设备和相应的试管(标称12毫克硅藻土激活剂)并行测量硅藻土ACT,使用HemoTec设备和相应的双管(标称0.1毫升高岭土激活剂)并行测量高岭土ACT。在ECC条件下,高岭土ACT值(482±145秒)显著低于硅藻土ACT值(985±267秒)。这些结果在使用活化部分凝血活酶时间(aPTT)模型的体外实验中得到了证实。仅使用肝素时,用硅藻土和高岭土激活的aPTT相似。在该模型中加入抑肽酶后,硅藻土aPTT与肝素浓度无相关性,而高岭土aPTT与肝素浓度仍保持良好相关性,且与未使用抑肽酶时的值相似。仅使用抑肽酶时,aPTT时间无变化,而硅藻土ACT时间无任何相关性。我们的结果表明,在抑肽酶治疗下,使用高岭土而非硅藻土进行ACT测量,其结果与未使用抑肽酶时处于相同范围:抑肽酶对高岭土激活的ACT无明显影响。我们认为,在ECC、肝素化和抑肽酶治疗条件下,应使用高岭土作为ACT测量的表面激活剂。(摘要截短于250字)